-
Women in India are the first in the world to receive new heat-stable carbetocin formulation to prevent excessive bleeding after childbirth
in PRESS RELEASE 2021 onAfter nearly a decade of public-private collaboration, Ferring Pharmaceuticals today announces the first use of heat-stable carbetocin (Carbetocin Ferring) for the prevention of excessive bleeding after birth, known as postpartum haemorrhage (PPH)…
-
Ferring Pharmaceuticals announces changes to Board of Directors
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Frederik Paulsen is stepping down from his role as Chairman of the Board of Directors* and transitioning to the role of Honorary Chairman. Lars Rebien Sørensen is appointed Chairman of the Board of Directors…
-
Ferring presents new data at ESHRE 2021 supporting the use of Rekovelle® (follitropin delta) for individualized fertility treatment
in PRESS RELEASE 2021 onNew data, presented today at the 37th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE), show a comparable ongoing pregnancy rate of 31.3% with the individualised dosing regimen of Rekovelle, compared to 25.7% with follitropin alfa…
-
Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
in PRESS RELEASE 2021 onFerring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for investigational microbiota-based live biotherapeutic RBX2660…
0 -
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
in PRESS RELEASE 2021 onFerring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection…
-
Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021
in PRESS RELEASE 2021 onFerring Pharmaceuticals and Rebiotix, a Ferring Company, today announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile (C. difficile) infection will be presented…
-
Ferring appoints Jan Lundberg to Group Board
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Jan Lundberg has been appointed to the Ferring Group Board, effective January 2021, as a non-executive director and Chairman of the Research and Development Committee, following the retirement of John Patterson…
-
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health
in PRESS RELEASE 2021 onFerring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive…
PRESS RELEASE 2021
PRESS RELEASE 2021
